Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.

Slides:



Advertisements
Similar presentations
Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung.
Advertisements

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.
Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma  Zoltan Lohinai, MD, Mir Alireza Hoda, MD,
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled.
Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,
Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer:
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S
Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.
Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled.
Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 
Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G
Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With.
The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.
A Phase II Study of PF in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207  Paul Wheatley-Price, MBChB, MD, Quincy Chu,
Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma  Naoki Yanagawa, MD, PhD, Charles.
Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 
Epidermal Growth Factor Receptor Mutations in 510 Finnish Non–Small-Cell Lung Cancer Patients  Satu Mäki-Nevala, MSc, Mikko Rönty, MD, Mike Morel, MBiolSci,
Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation  Jean-Yves.
A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review.
A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium 
Clinical Outcome of ALK-Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors.
Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non–Small Cell Lung Cancer  Junghoon Shin, MD, Bhumsuk Keam, MD, PhD, Miso.
Prognostic and Predictive Effect of TP53 Mutations in Patients with Non–Small Cell Lung Cancer from Adjuvant Cisplatin–Based Therapy Randomized Trials: A.
Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors  Su Jin Lee, MD, Jung-Il Lee,
PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer  Denis Soulières, MD, Fred R.
Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung.
Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib 
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung.
Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations  Benjamin Haaland, PhD, Pui San Tan,
Pyrosequencing Analysis of EGFR and KRAS Mutations in EUS and EBUS-Derived Cytologic Samples of Adenocarcinomas of the Lung  Jos A. Stigt, MD, Nils A.
Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer 
EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases  Tao.
Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature  Caicun Zhou, MD, PhD, Luan Di Yao, MD 
PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?  Steven G. Gray, PhD  Journal of Thoracic.
Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis  Bin-Chi Liao,
Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung.
Erratum Journal of Thoracic Oncology
Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.
Natural History and Factors Associated with Overall Survival in Stage IV ALK- Rearranged Non–Small Cell Lung Cancer  Jose M. Pacheco, MD, Dexiang Gao,
Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non- small Cell Lung Cancer Patients Aged 70 Years or Older  Yuh-Min Chen,
Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed  Emanuela Taioli, MD, PhD, Raja Flores, MD 
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta- analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in.
MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation  Ling Huang, MS, She-Juan An, PhD, Zhi-Hong.
EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer  Allison Ackerman, MD, Michael A. Goldstein,
Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung.
Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib or Placebo in.
Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors 
Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer  Emily Castellanos, MD, Emily Feld, MD, Leora.
Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local.
KRAS Mutations in Advanced Nonsquamous Non–Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value 
Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone?  Alvaro Leone, BSc.D 
Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study  Giorgio V.
Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small- Cell Lung Cancer  Jih-Hsiang Lee, MD, Yu-Lin Lin, MD, Wei-Hsun Hsu,
Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for.
The Current Role of Whole Brain Radiation Therapy in Non–Small Cell Lung Cancer Patients  Gokoulakrichenane Loganadane, MD, Lizza Hendriks, MD, PhD, Cécile.
Presentation transcript:

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors  Alona Zer, MD, Keyue Ding, PhD, Siow Ming Lee, MD, Glenwood D. Goss, MD, Lesley Seymour, MD, Peter M. Ellis, PhD, Allan Hackshaw, MSc, Penelope A. Bradbury, MBBCh, Lei Han, MSc, Christopher J. O’Callaghan, PhD, Ming-Sound Tsao, MD, Frances A. Shepherd, MD  Journal of Thoracic Oncology  Volume 11, Issue 3, Pages 312-323 (March 2016) DOI: 10.1016/j.jtho.2015.11.010 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Consort diagram. NCIC CTG, National Cancer Institute of Canada Clinical Trials Group; NSCLC, non–small cell lung cancer; KRAS, Kirsten rat sarcoma viral oncogene homolog; E-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; WT, wild-type; MUT, mutated; G, guanine; T, thymidine; A, adenine; C, cytosine. Journal of Thoracic Oncology 2016 11, 312-323DOI: (10.1016/j.jtho.2015.11.010) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Prognostic effect of KRAS on overall survival for patients in the placebo arms. KRAS, Kirsten rat sarcoma viral oncogene homolog; HR, hazard ratio; CI, confidence interval. Journal of Thoracic Oncology 2016 11, 312-323DOI: (10.1016/j.jtho.2015.11.010) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Overall survival benefit from EGFR TKIs compared with placebo. WT, wild-type; MUT, mutated; EGFR TKIs, epidermal growth factor receptor tyrosine kinase inhibitors; KRAS, Kirsten rat sarcoma viral oncogene homolog; HR, hazard ratio; CI, confidence interval. Journal of Thoracic Oncology 2016 11, 312-323DOI: (10.1016/j.jtho.2015.11.010) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 4 Overall survival benefit from EGFR TKIs compared with placebo according to KRAS mutation subtypes. MUT, mutated; EGFR TKIs, epidermal growth factor receptor tyrosine kinase inhibitors; KRAS, Kirsten rat sarcoma viral oncogene homolog; HR, hazard ratio; CI, confidence interval. Journal of Thoracic Oncology 2016 11, 312-323DOI: (10.1016/j.jtho.2015.11.010) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions